Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial-Reference-Cited by-同舟云学术

Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial

Published:2012-09 Issue:9 Volume:13 Page:869-878
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Ismael Gustavo,Hegg Roberto,Muehlbauer Susanne,Heinzmann Dominik,Lum Bert,Kim Sung-Bae,Pienkowski Tadeusz,Lichinitser Mikhail,Semiglazov Vladimir,Melichar Bohuslav,Jackisch Christian

Publisher

Elsevier BV

Subject

Oncology

Reference16 articles.

1. Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up;Aebi;Ann Oncol,2011

2. Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up;Cardoso;Ann Oncol,2011

3. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011;Goldhirsch;Ann Oncol,2011

4. A recombinant human enzyme for enhanced interstitial transport of therapeutics;Bookbinder;J Control Release,2006

5. Converting intravenous dosing to subcutaneous dosing with recombinant human hyaluronidase;Haller;Pharm Tech,2007

Cited by 298 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current advances in non-viral nanoparticle-based gene therapy for effective management of cancer;Journal of Drug Delivery Science and Technology;2024-10

2. Pharmacokinetics of trastuzumab and its efficacy and safety in HER2-positive cancer patients;Cancer Chemotherapy and Pharmacology;2024-08-23

3. Landscape of Subcutaneous Administration Strategies for Monoclonal Antibodies in Oncology;Advanced Materials;2024-08-20

4. An innovative model of delivering cancer care in the community: the experience of a tertiary cancer centre in Singapore;ESMO Open;2024-07

5. Pharmacological properties and clinical development overview of pertuzumab (genetical recombination), trastuzumab (genetical recombination) and vorhyaluronidase alfa (genetical recombination) (PHESGO<sup>®</sup> combination for ‍subcutaneous injection MA, IN);Folia Pharmacologica Japonica;2024-07-01